

04/25/01  
U.S. PTO

04 - 27 - 01

A  
PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → 

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. §1.53(b))

Attorney Docket No. PC10583ADAM

First Named Inventor or Application Identifier Barbara Foster, et al.

Title Assay Method for Cyclin Dependent Kinases

Express Mail Label No. EL710829944US

04/25/01  
092 843462

04/25/01

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  \*Fee Transmittal Form (e.g., PTO/SB/17)  
*(Submit an original, and a duplicate for fee processing)*
2.  Specification [Total Pages 23]  
*(preferred arrangement set forth below)*
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference in Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings *(if filed)*
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3.  Drawing(s) (35 U.S.C. 11.3) [Total sheets 1]
4.  Oath or Declaration [Total pages 4]
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 CFR §1.63(d))  
*(for continuation/divisional with Box 17 completed)*  
**[Note Box 5 below]**
    - i.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).
5.  Incorporation By Reference *(useable if Box 4b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO:  
Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

6.  Microfiche Computer Program (Appendix)
7.  Nucleotide and/or Amino Acid Sequence Submission  
*(if applicable, all necessary)*
  - a.  Computer Readable Copy
  - b.  Paper Copy (identical to computer copy)
  - c.  Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8.  Assignment Papers (cover sheet & document(s))
9.  37 C.F.R. §3 73(b) Statement  Power of Attorney  
*(when there is an assignee)*
10.  English Translation Document *(if applicable)*
11.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations
12.  Preliminary Amendment
13.  Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*
14.  \*Small Entity  Statement filed in prior application, Statement(s)  Status still proper and desired (PTO/SB/09-12)
15.  Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
14.  Other:

\*NOTE FOR ITEMS 1 &amp; 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

 Continuation  Divisional  Continuation-in-part (CIP) of prior application No: /

Prior application information: Examiner \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

## 18. CORRESPONDENCE ADDRESS

(Insert Customer No. or Attach bar code label here)

or  Correspondence address below

Name	Gregg C. Benson				
Address	Pfizer Inc.				
Address	Patent Department, MS 4159, Eastern Point Road				
City	Groton	State	CT	Zip Code	06340
Country	United States Of America	Telephone	1-(860)-441-4901		Fax 1-(860)-441-5221

NAME (Print/type)	Deborah A. Martin
Signature	<i>Deborah A. Martin</i>

Registration No. (Attorney/Agent) 44,222

Date

4-25-01

## FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.  
These are the fees effective October 1., 2000.

Small Entity payments **must** be supported by a small entity statement,  
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.


See 37 C.F.R. §§ 1.27 and 1.28.

**Total Amount of Payment** (\$764.00)

METHOD OF PAYMENT (check one)		FEE CALCULATION (continued)				
1. <input checked="" type="checkbox"/> The commissioner is hereby authorized to charge indicated fees and credit any over payments to:		3. ADDITIONAL FEES				
Deposit Account Number	16-1445	Large Entity				
Deposit Account Name	Pfizer Inc	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
<input checked="" type="checkbox"/> Charge Any Additional 37 Fee Required Under C.F.R. §§ 1.16 and 1.17.		105	130	205	65	Surcharge – late fee or oath
<input type="checkbox"/> Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance		127	50	227	25	Surcharge–late provisional filing fee or cover sheet
2. <input type="checkbox"/> Payment Enclosed:  <input type="checkbox"/> Check <input type="checkbox"/> Money Order <input type="checkbox"/> Other		139	130	139	130	Non-English specification
		147	2,520	147	2,520	For filing a request for reexamination
		112	920*	112	920*	Requesting publication of SIR prior to Examiner action
		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action
		115	110	215	55	Extension for reply within first month
		116	390	216	195	Extension for reply within second month
		117	890	217	445	Extension for reply within third month
		118	1,390	218	695	Extension for reply within fourth month
		128	1,890	228	945	Extension for reply within fifth month
		119	310	219	155	Notice of Appeal
		120	310	220	155	Filing a brief in support of an appeal
		121	270	221	135	Request for oral hearing
		138	1,510	138	1,510	Petition to institute a public use proceeding
		140	110	240	55	Petition to revive - unavoidable
		141	1,240	241	620	Petition to revive - unintentional
		142	1,240	242	620	Utility issue fee (or reissue)
		143	440	243	220	Design issue fee
		144	600	244	300	Plant issue fee
		122	130	122	130	Petitions to the Commissioner
		123	50	123	50	Petitions related to provisional applications
		126	240	126	240	Submission of Information Disclosure Statement
		581	40	581	40	Recording each patent assignment per property (times number of properties)
		146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))
		149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))
		Other Fee (specify)				
		Other Fee (specify)				
		*Reduced by Basic Filing Fee Paid				
		SUBTOTAL (3) (\$)				
		0				

## SUBMITTED BY

Type or Printed Name Deborah A. Martin

Signature 

Complete (if Applicable)

Reg. Number 44,222

Deposit Account User ID 16-1445

EXPRESS MAIL NO. EL710829944US

FEE TRANSMITTAL PTO SB 17.DOT 10/00